Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Inclusion Criteria:

• Cytologically or histologically and radiologically confirmed solid tumor that isinoperable, locally advanced, metastatic, or recurrent.

• Dose-Escalation Stage Cohorts A, AB, and AN: The subject has received at least onesystemic standard life-prolonging therapy unless it does not exist, or availabletherapies are intolerable or no longer effective.

• Cohort-Expansion Stage (Cohorts B - M, BN, FN and HN): The subject has receivedstandard life-prolonging therapies unless they do not exist, or available therapiesare intolerable or no longer effective.

• Cohort-Expansion Stage Cohort B and BN (Non-small Cell Lung Cancer): Subjects withStage IV NSCLC who have documented radiographic disease progression during orfollowing their last systemic anticancer therapy.

• Cohort-Expansion Stage Cohort D (Epithelial Ovarian Cancer): Subjects withhigh-grade serous ovarian cancer, including primary peritoneal cancer (PPC) andfallopian tube cancer (FTC) who have platinum-resistant disease following treatmentwith platinum-containing chemotherapy.

• Cohort-Expansion Stage Cohort E (Cervical Cancer): Subjects with persistent,recurrent, or metastatic carcinoma of the uterine cervix who have documentedradiographic disease progression during or following their last systemic anticancertherapy.

• Cohorts F and FN (SCCHN): Subjects with head and neck cancer (squamous cellhistology) who have documented radiographic disease progression during or followingtheir last systemic anticancer therapy. Allowed primary tumor locations are oralcavity, oropharynx, hypopharynx, glottic larynx. Note: Excluded are subjects withprimary tumor site of the nasopharynx.

• Cohort G (Pancreatic Cancer): Subjects with pancreatic cancer (adenocarcinomahistology) who have documented radiographic disease progression during or followingtheir last systemic anticancer therapy.

• Cohort H (Esophageal SCC): Subjects with esophageal cancer (squamous cell histology)who have documented radiographic disease progression during or following their lastsystemic anticancer therapy. Note: subjects with esophageal adenocarcinoma andadenocarcinoma of gastroesophageal junction (GEJ) are excluded.

• Cohort I (mCRPC): Subjects with metastatic, castration resistant adenocarcinoma ofthe prostate. Note: Neuroendocrine differentiation and other histological featuresare permitted if adenocarcinoma is the primary histology.

• Cohort J (TNBC): Subjects with triple-negative (estrogen receptor negative [ER-]/progesterone receptor negative [PR-]/ human epidermal growth factor receptor 2negative [HER-2-]) breast cancer who have documented radiographic diseaseprogression during or following their last systemic anticancer therapy forinoperable locally advanced or metastatic disease.

• Cohort K (HR + BC): Subjects with breast cancer that is hormone receptor-positive (ER+ and/or PR+) and HER-2-) and who have documented radiographic diseaseprogression during or following their last systemic anticancer therapy forinoperable locally advanced or metastatic disease.

• Cohort L (Endometrial Cancer): Subjects with locally advanced, recurrent ormetastatic endometrial cancer who have documented radiographic disease progressionduring or following their last systemic anticancer therapy.

• Cohort M (Tumor-Agnostic Tissue Factor-Expressing Solid Tumors): Subjects with solidtumors other than those designated in Cohorts B-L and those which express tissuefactor. Participation in this cohort will be at selected sites and countries basedon site feasibility assessment.

• Expansion Cohorts: Subjects must have measurable disease per RECIST 1.1 asdetermined by the Investigator, except for subjects with prostate cancer withoutsoft tissue disease and subjects with primary brain tumors.

• Tumor tissue material collected no more than 3 years prior to consent, if possible.If archival tumor tissue is not available, a fresh tumor biopsy may be collectedfrom subjects enrolled in the Dose-Escalation Stage and should be collected fromsubjects in the Cohort-Expansion Stage.

• Recovery to baseline or ≤ Grade 1 severity (Common Terminology Criteria for AdverseEvents version 5 [CTCAE v5]) from AEs.

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.

• Adequate organ and marrow function.

• Sexually active fertile subjects and their partners must agree to use medicallyaccepted methods of contraception.

• Female subjects of childbearing potential must not be pregnant at screening.

Exclusion Criteria:

• Receipt of prior therapies as defined in study protocol

• Known brain metastases or cranial epidural disease unless adequately treated withradiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeksbefore first dose of study treatment.

• Uncontrolled, significant intercurrent or recent illness.

• Major surgery within 4 weeks before first dose of study treatment

• Corrected QT interval calculated by the Fridericia formula (QTcF) > 480 ms perelectrocardiogram (ECG).

• Pregnant or lactating females

• Previously identified allergy or hypersensitivity to components of study treatmentformulations or history of severe infusion-related reactions to monoclonalantibodies.

• Another unresolved malignancy or a malignancy that is considered to be cured within 2 years before first dose of study treatment. Note: Subjects with superficialnon-melanoma skin cancers, or localized, low grade tumors deemed cured and nottreated with systemic therapy within 2 years before first dose of study treatmentare eligible.